Background: Cervical carcinoma is a leading cause of mortality from cancer among women worldwide, accounting for approximately 160 000 deaths annually. Prognosis in patients with this disease is dependent on several well-established clinical features (stage of disease and age of patient) and pathologic features (lymph node status, grade of tumor, and depth of invasion). Although the features associated with poor clinical outcome have been well studied, molecular markers such as human papillomavirus (HPV) type that may reflect the underlying biologic basis for clinical behavior are poorly understood. Purpose: To test the hypothesis that differences in survival among patients with cervical carcinoma are associated with HPV DNA type, we conducted a historical cohort study of patients treated at our institutions over a 10-year period. Methods: Fresh primary tumor tissue samples from 291 women with all stages of cervical carcinoma diagnosed from April 1983 through August 1993 were rapidly frozen and stored at -70 °C until analysis. High-molecular-weight DNA was extracted and purified by homogenization, proteinase K digestion, phenol extraction, ammonium acetate salt displacement, ethanol precipitation, and ribonuclease treatment. HPV nucleotide sequences were amplified from tumor DNA samples by polymerase chain reaction with the use of both consensus LI (MY09/MY11) primers that recognize more than 25 HPV types and modifications of type-specific primers developed for HPV types 16, 18, and 6. Clinical data were abstracted from hospital, office, and tumor registry records. Univariate analysis was conducted using Student's t test and chisquared tests. Survival curves were estimated by use of the Kaplan-Meier method; differences between groups were examined by the logrank test. Multivariate survival analysis was performed according to the Cox proportional hazards model. Results: HPV DNA was detected in 247 (85%) of 291 tumors: HPV16 in 52%, HPV18 in 20%, other HPV types in 13%, and no HPV DNA in 15%. Eighty-eight percent of squamous tumors contained HPV DNA compared with 79% of adenocarcinomas, the latter harboring predominantly
Cervical carcinoma is a leading cause of mortality from cancer among women worldwide, accounting for approximately 160 000 deaths yearly (7) . Prognosis in patients with this disease is dependent on several well-established clinical and pathologic features. A recent multivariate analysis of more than 17 000 cases of cervical cancer in the United States registered between 1973 and 1987 by the Surveillance, Epidemiology, and End Results (SEER) Program 1 identified the following factors to be predictors of survival: International Federation of Gynecology and Obstetrics (FIGO) stage, patient age, lymph node status, grade, and histology (2) . In this analysis, advanced stage, older age, pelvic lymph node metastases, high grade, and adenosquamous histology were shown to be independent, adverse prognostic factors. Although the pathologic and clinical features associated with poor clinical outcome have been well studied, molecular markers that may reflect the underlying biologic basis for clinical behavior are poorly understood.
A sexually transmitted agent has long been suspected to cause cervical cancer. During the last decade, substantial evidence has suggested that the human papillomavirus (HPV) is that agent (3) (4) (5) . The papillomavirus family is a remarkably diverse group of viruses with more than 70 different genotypes identified by DNA homology (6) . More than 35 types are known to infect the human anogenital tract, and at least 20 types are associated with invasive cancers (3) (4) (5) (6) ; however, only a few of these types are common in cervical cancer. In a recent series of more than 1000 cervical cancer patients from 22 countries, HPV 16 was present in 50% of their tumors, followed by HPV 18 in 14%, HPV45 in 8%,andHPV31 in 5% (3).
It is not clear if the presence of HPV or a specific genotype in a tumor has any clinical relevance. The validity of conclusions regarding clinicopathologic associations ultimately depends on both the sensitivity of HPV detection and the accuracy of HPV typing, inasmuch as minor errors in classification of the HPV status of lesions can have a major impact on the conclusions reached (7, 5) . We have demonstrated the improved accuracy of the polymerase chain reaction (PCR) technique over Southern blot hybridization in a study of HPV typing in 242 invasive genital cancers analyzed simultaneously by both techniques (9) . As expected, 60% of the samples found negative for HPV by Southern blot analysis were found to be positive by PCR, and there was excellent agreement between two sets of PCR primers for detection of HPV6, HPV 16, and HPV 18. Data are conflicting about the influence of HPV status on cervical carcinoma prognosis. Using Southern blot data, we (70) previously reported that patients with HPV18-containing tumors have a worse prognosis than those with HPV16-associated tumors. Other investigators have reported that women with HPV 18 in their tumors are at increased risk of lymph node metastases (77,72) and disease recurrence (12) (13) (14) . In addition, HPV 18 has been associated with more advanced (15) and more rapidly progressing (76) intraepithelial lesions. There is also experimental evidence for increased oncogenicity of HPV 18, inasmuch as this viral genotype transforms keratinocytes more efficiently than HPV 16 (17,18) . In contrast, other researchers have shown that HPV type does not influence survival or that patients who had no HPV detected in their tumors have a worse prognosis than those with tumors containing either HPV16orHPV18(2J-2<5).
To test the hypothesis that differences in survival among patients with cervical carcinoma are associated with HPV DNA type, we conducted a historical cohort study of patients treated at our institutions over a 10-year period. Genomic DNA from fresh tissue of newly diagnosed patients with cervical cancer was analyzed for HPV DNA type by PCR. The presence of HPV DNA as well as the genotype was tested for association with important clinicopathologic variables and survival.
Materials and Methods
Tumor sample preparation. From April 1983 through August 1993, fresh primary tumor tissue was obtained from 291 patients with cervical carcinoma whose disease had been staged and who had received primary treatment at the University of California, Irvine Medical Center, or at the City of Hope National Medical Center or their two affiliated institutions. The study was approved by the institutional review boards at all institutions in accord with assurances filed with and approved by the U.S. Department of Health and Human Services. In order to exclude sampling of associated dysplastic or condylomatous tissue, care was taken to harvest tumor tissue devoid of visible surface epithelium. After excision, tissue samples were rapidly frozen at -70 °C.
DNA extraction. High-molecular-weight DNA was extracted from frozen tissue and purified by homogenization, proteinase K digestion, phenol extraction, ammonium acetate salt displacement, ethanol precipitation, and ribonuclease treatment as previously described (9) . In each case, the presence of invasive cancer in tissue undergoing DNA extraction was histologically confirmed by light microscopy on hematoxylin-eosin-stained, paraffin-embedded sections of immediately adjacent, frozen tissue, as well as by histologic examination of a representative fraction of the sample actually extracted. DNA extracted from the tumors was amplified with (3-globin primers to monitor the integrity of the DNA (9), and only tumors that amplified were included in the study. HPV nucleotide sequences were amplified from purified tumor DNA samples by PCR under conditions previously described (9) with the use of both consensus LI (MY09/MY11) primers, as reported by Ting and Manos (27) , that recognize more than 25 HPV types and modifications of type-specific primers developed by Dallas et al. (28) for HPV 16, HPV 18, and HPV6. HPV type was then determined by methods previously described (9) . In this study, tumors that did not amplify or hybridize with the type-specific primers or that failed to give a 450-base-pair (bp) product on agarose gels stained with ethidium bromide after amplification with the consensus primers were considered to lack detectable HPV DNA.
Assignment of HPV type. The HPV typing of the cases was done without knowledge of the clinical follow-up information. Eighty-eight of the patients in this study were also included in our previous report of HPV association with prognosis in 100 women with cervical cancer (10) . In this earlier study, the HPV type was determined only by Southern blot analysis. For the current study, all cases with available DNA (88 of the 100 cases) were reanalyzed by PCR as described above, and the PCR results were used for this study.
Stage, histologic classification, and grading of tumors. The patient's clinical disease stage was determined with the use of standard FIGO criteria (29) . The histologic classification and grading of the tumors were performed as previously described (30) .
Clinical data collection and statistical analysis. Clinical data were abstracted from hospital, office, and tumor registry records. Statistics were compiled and analyzed using the SAS program (version 6: SAS Institute. Inc., Cary, NC). The relationship between patient age and inclusion in the study was calculated by use of a two-tailed Student's t test. The associations of FIGO stage, histologic cell type, tumor grade, and primary' therapy with inclusion in the study were evaluated by use of chi-squared tests; adjustments were made for multiple comparisons by the method of Bonferroni. Associations between HPV DNA type and dichotomized clinicopathologic variables were also analyzed by chisquared tests. Follow-up was calculated among individuals alive at the time of data analysis. Survival curves were estimated by use of the Kaplan-Meier method; a two-tailed logrank test was used to determine differences. Patients who died of causes unrelated to cervical cancer were censored at the date of death during analysis of survival. By use of the Cox proportional hazards model, multivariate analysis was performed to determine the independent impact on survival of HPV DNA type as well as important epidemiologic and clinicopathologic variables. For patients with stage IB or IIA disease who were undergoing type III radical hysterectomy (removal of uterus and upper vagina along with other tissues extending to the pelvic wall) with bilateral pelvic lymphadenectomy, multivariate survival analysis was conducted for HPV type, the presence of lymph node metastases. depth of cervical stromal invasion, tumor grade, and histologic cell type. The proportional hazards assumption of the Cox model was tested by the examination of residuals. For all statistical tests, the level of significance was set at .05.
Results
From April 1983 through August 1993, during the period of tumor collection at each institution, 888 patients with newly diagnosed cervical carcinoma were referred to the City of Hope National Medical Center or to the University of California, Irvine Medical Center, or their two affiliated institutions. Fresh primary tumor tissue from 291 (33%) patients was available for HPV typing. These 291 patients represent the study population. The mean age of the study group at diagnosis was 45 years (range, 20-84 years). One hundred ninety-one (66%) of these patients had FIGO stage I lesions, whereas 56 (19%), 36 (12%), and eight (3%) had stage II, III, or IV disease, respectively. Twenty-six (9%) cancers were well differentiated, 128 (44%) were moderately differentiated, and 132 (45%) were poorly differentiated. Tumor grade was determined for 286 of the 291 tumors; five (2%) minimally invasive cancers were excluded. The majority of tumors were squamous cell carcinomas (n = 202, 69%); adenocarcinomas (n = 56, 19%), adenosquamous carcinomas (n -29, 10%), and other histologic cell types (n = 4, 1%) were less common.
Therapy was based primarily on tumor stage and geometry, as well as on the medical condition and preference of the patient. Among the 606 patients in the total cervical cancer population with stage I or IIA disease, 447 (74%) underwent standard type III radical hysterectomy and pelvic lymphadenectomy (37) . One hundred seventy-one (38%) of these patients are included in the study population. Adjuvant pelvic radiotherapy was prescribed after radical hysterectomy to patients with deep stromal invasion, parametrial extension, or lymph node metastases (52). Patients who were not surgical candidates typically received primary pelvic irradiation consisting of 45-to 50-Gy whole-pelvic teletherapy and two brachytherapy insertions delivering mean tumor doses of approximately 40 Gy. At the conclusion of primary treatment, patients were in general followed at 3-month intervals for the first 2 years and at 6-month intervals thereafter.
The study population did not differ from the total population of women referred with cervical cancer with respect to histologic cell type and tumor grade; however, it did differ with respect to FIGO stage, therapy, and patient age. Only seven (2%) of the 291 study patients had FIGO stage IA2 lesions, and none had stage IA1 disease. In contrast, 91 (15%) of the 597 patients for whom tissue was not available for DNA extraction had stage IA1 or IA2 cancer. Patients with microinvasive tumors (stage IA) were treated with less aggressive therapy, usually a simple hysterectomy, and tissue for HPV studies was usually not available. Similarly, tissue was less likely to be available from patients from whom only biopsy specimens were obtained and who were then treated with radiation therapy either because of inoperability of the tumor (stage III or IV) or because of concurrent medical problems that tended to occur in older women. However, when only the subgroup of patients treated with radical surgery was considered, patients in the study population did not differ significantly from similar patients in the source population with respect to mean age (44.1 years and 45.6 years, respectively), stage, histologic cell type, or tumor grade.
HPV DNA was detected in 85% of the 291 specimens analyzed. HPV 16 was the most common type identified and occurred in 52%. In contrast, HPV 18 and other HPV types were detected in 20% and 13%, respectively. The relationship between epidemiologic characteristics of the study population and HPV DNA status is summarized in Table 1 . Patients 45 years of age or younger or those with a history of cigarette smoking were more likely to have HPV detected in their cervical cancers than women older than 45 years or without a history of cigarette smoking. As illustrated in Table 2 , there was no statistically significant association of FIGO stage of disease and tumor grade with HPV type. As expected, adenocarcinomas and adenosquamous carcinomas were significantly more likely to contain HPV 18 DNA than squamous cell carcinomas; likewise, squamous cell carcinomas were significantly more likely to contain HPV 16 DNA than adenocarcinomas or adenosquamous tumors (P = .001). Although not statistically significant, there was a trend for cancers in which HPV DNA was not detected to be more often adenomatous and adenosquamous than squamous (P = .14). Among the entire study group, neither HPV status nor HPV type was prognostic of recurrence-free interval (data not shown) or survival (Table 3) .
During the study period, a group of four senior board-certified gynecologic oncologists at the City of Hope National Medical Center and the University of California, Irvine Medical (20) 31 (16) 12 (13) 31 (20) 9 (8) 21 (15) 22 (16) the uterine artery at its origin, division of the cardinal and uterosacral ligaments adjacent to the pelvic wall, resection of the upper third of the vagina, and dissection of the pelvic ureter to the base of the urinary bladder. All lymph node-bearing adipose tissue from the obturator, external iliac, hypogastric, and common iliac groups was resected. Because the 171 patients undergoing type III radical hysterectomy and pelvic lymphadenectomy represented a homogeneously treated, "surgically staged" population with unique histopathologic end points, this subgroup was analyzed separately. Some associations of HPV type with epidemiologic and histopathologic characteristics in the entire study population were also demonstrated in this subset of patients. First, those who had a history of cigarette smoking were more likely to have tumors that contained HPV DNA than those without such a history. Second, adenocarcinomas and adenosquamous tumors were associated with HPV 18, whereas squamous lesions were associated with HPV 16. However, an association between age and HPV DNA status could no longer be demonstrated in this subset of patients. Similarly, ethnicity, gravidity, tumor grade, and FIGO stage were not associated with HPV DNA status or type. Finally, because of their well-known prognostic importance in early stage disease, depth of cervical stromal invasion and pelvic lymph node status were also analyzed in the subgroup treated with radical hysterectomy and pelvic lymphadenectomy. No statistically significant relationship was found between either depth of stromal invasion (inner and middle third versus outer third) or lymph node status (negative versus positive pelvic lymph nodes) and HPV type (HPV detected versus HPV not detected, P = .88 and P = .28, respectively; HPV 16 versus HPV 18, P -.49 and P -.19, respectively; and HPV 18 versus all others, P -.46 and P = .21, respectively).
Among the 171 patients with stage IB or IIA disease treated with radical hysterectomy and pelvic lymphadenectomy, there was no difference in estimated 5-year survival rates with respect to age, tumor grade, and cell type. As expected, however, survival was associated with both depth of stromal invasion and lymph node status. The calculated 5-year survivals according to depth of stromal invasion were 97%, 89%, and 69% for those with inner, middle, and outer third invasion, respectively (P = .008). In addition, patients with negative lymph nodes had an estimated 5-year survival of 90% compared with 56% for those with positive lymph nodes (P -.001).
Survival was also associated with HPV type in women with cervical carcinoma treated with radical hysterectomy and pelvic lymphadenectomy. Estimated 5-year survivals (95% confidence intervals) according to HPV type were as follows: 84% (80%-88%) for those with HPV16-containing tumors, 59% (48%-70%) for those with HPV18-containing tumors, and 77% (64%-90%) for those in whom no HPV was detected in their tumors. Estimated 3-year survivals were also calculated, yielding a similar pattern (data not shown); however, there was overlap between 95% confidence intervals for 3-year survival in patients with HPV 18-containing tumors and those in patients with HPV16-associated tumors. The survival of women with cervical cancers containing HPV 18 DNA was statistically worse than the survival of those with cervical cancers containing HPV 16 (P = .023). In addition, when the survival of those with tumors containing HPV 18 DNA was compared with that of all other patients treated with radical hysterectomy and bilateral pelvic lymphadenectomy, this difference was also statistically significant (P = .025). The relatively poor survival of women with HPV 18-containing tumors is shown graphically in Fig. 1 . When multivariate analysis was performed, the poor prognostic significance of HPV 18 DNA among women with cervical cancers treated with radical hysterectomy and pelvic lymphadenectomy was independent of lymph node status, depth of stromal invasion, tumor grade, and histologic cell type (Table 4) .
Discussion
This study reports the clinicopathologic findings on 291 women whose cervical cancers were analyzed for HPV DNA by PCR. The most consistent clinicopathologic association of HPV The 5-year survival estimates (95% confidence intervals) according to HPV type were as follows: 84% (80%-88%) for those with HPV16-containing tumors, 59% (48%-70%) for those with HPV 18-containing tumors, and 77% (64%-90%) for those in whom no HPV was detected in their tumors.
genotype with cervical cancers has been the observation that HPV 18 is found predominantly in adenocarcinomas of the cervix, whereas HPV 16 is the most common HPV type in tumors with squamous histology (3^0,21^4^5^3,34 ). This strong association of HPV 18 with glandular differentiation is also found in the current series of cervical cancers. Of the cervical cancers that were histologically classified as either adenocarcinoma or adenosquamous carcinoma, 62% (36 of 58) contained HPV 18 DNA. However, HPV 18 was found in only 20% of the tumors analyzed (n = 291), and the majority of squamous cell carcinomas (61%) contained HPV 16 DNA. The histopathologic relationship between HPV 18 and glandular differentiation also holds true for the subset of patients with early stage disease who were treated with radical hysterectomy and pelvic lymphadenectomy. The molecular mechanisms for the association of HPV 18 with glandular lesions are not understood. It is unlikely that cellular receptors for viral particles determine specificity, inasmuch as papillomaviruses bind to and are internalized by a wide variety of eukaryotic cells (55). The available evidence suggests that tissue specificity of the individual HPV types is determined by a complex interplay among cellular transcription factors and the control elements in the viral regulatory region (36, 57) .
In this study, we confirmed an increased proportion of HPVcontaining invasive lesions in younger women and in those with a history of cigarette smoking (3J8). Although this observation has not been demonstrated in all epidemiologic studies, the biologic plausibility of these findings is supported by in vitro data demonstrating that nicotine increases the transforming potential of HPV in human cervical epithelial cells (39) .
The prognostic significance of HPV in invasive cervical cancer is controversial (40) because contradictory observations have been reported (10) (11) (12) (13) (14) (19) (20) (21) (22) (23) (24) (25) (26) . The results of these studies are summarized in Table 5 . Several studies have shown no association between the presence or type of HPV in cervical cancer with outcome (19) (20) (21) (22) , whereas others have demonstrated that patients with no HPV detected in their tumors have a worse prognosis than those with HPV-positive lesions (23) (24) (25) (26) . In this series, the overall proportion of cervical cancers with HPV was 85%, similar to other reports (4£). However, studies in which consensus PCR products were hybridized with a generic HPV probe reportedly detected papillomaviruses in up to 93% of cervical cancers (3). It is becoming apparent that cervical cancers that are truly HPV negative are rare and that identification of HPV in tumor DNA increases as more sensitive methods of detection are utilized. It is likely that the tumors in which no HPV DNA is detected comprise a heterogeneous group that includes tumors that are truly HPV negative, those with low viral copy numbers, and those having HPV types that amplify poorly or not at all with the currently available consensus primers. Therefore, the reported association of worse clinical outcome in cervical cancer patients in whom no HPV DNA was detected in their tumors compared with women with HPV-positive cancers may be related to increased oncogenicity of HPV types that are more difficult to detect, such as HPV 18. Data are accumulating that the presence of HPV 18 in early stage cervical cancer may predict a more biologically aggressive tumor. In our study, among patients with stage IB or HA tumors treated with type III radical hysterectomy and pelvic lymphadenectomy, women whose tumors harbored HPV 18 had poorer survival than women whose lesions contained HPV 16. In a recently published series (14) , the HPV types were analyzed in 74 recurrent and 74 nonrecurrent stage IB or IIA cervical cancers treated by radical hysterectomy. HPV 18 was found in the tumors of 31 % of the patients who had disease recurrence and only 14% of the patients who did not have disease recurrence. On a molecular level, there is strong evidence to suggest that HPV 18 has increased oncogenic potential, inasmuch as it has five times the transforming activity as that of HPV 16 in cell culture systems (17) . There is no difference, however, in the immortalization activity of HPV 16 and HPV 18 oncoproteins E6 and E7 (41) . The increased transforming ability of HPV 18 maps to the untranslated, viral control region (long control region [LCR]) (18); yet it is not clear how the sequence variation in this region controls the biologic behavior of the different HPV types. Other as yet poorly understood immunologic differences in the host response to HPV 18 may also be involved in its increased virulence. Evidence (42) suggests that the susceptibility of HPV-infected individuals to develop cervical neoplasia and the biologic behavior of such neoplastic lesions may be governed by specific human leukocyte antigen (HLA) haplotypes.
Although the underlying molecular mechanisms for determining the oncogenic potential of HPV types are not understood, it may be clinically useful to identify the type of HPV in early stage cervical cancers. Our study demonstrates that, in the population of women treated for cervical cancer by radical hysterectomy and pelvic lymphadenectomy, the presence of HPV type 18 DNA in the tumor was an independent poor prognostic factor. Perhaps if HPV 18 is identified in the tumors of women who have, by standard clinical and pathologic assessment, otherwise favorable prognoses, additional postoperative therapy may be warranted. It will be necessary to conduct prospective, multi-institutional, controlled studies to determine if HPV genotype can be used to direct therapy of selected cervical cancer patients.
